Psoriasis patients weigh in: is wynzora cream the new favorite?

NCT ID NCT06180473

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looked at whether people with mild-to-moderate psoriasis prefer using Wynzora cream over Enstilar foam. Thirty adults who had previously used Enstilar foam tried Wynzora cream for four weeks. Researchers used questionnaires to measure preference, treatment satisfaction, and how well patients followed their treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Wynzora cream (calcipotriene and betamethasone dipropionate)

What this could lead to

If successful, this could show that Wynzora cream is a more preferred or easier-to-use option for managing mild-to-moderate psoriasis compared to Enstilar foam.

What could go wrong

This is a small, completed study with only 30 participants, so results may not apply to everyone. It measures preference and adherence, not long-term disease control or cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Policlinico Agostino Gemelli

    Rome, Italy